Investment In Bioscience Companies
SB119 amends the Bioscience Development Act to authorize the New Mexico bioscience authority to make direct investments in bioscience companies, rather than only providing traditional financial assistance. The bill defines bioscience broadly to include drugs and pharmaceuticals, medical devices, research and medical laboratories, bioscience distribution, and related agriculture and chemicals, and it expands the act’s definitions to include a “portfolio business” and clarifies the meaning of a New Mexico business.
The measure creates detailed requirements for eligible investments. A business must either already be a New Mexico business with at least five in-state employees earning an average annual salary of $60,000, or agree to relocate to New Mexico and maintain that workforce and salary level for at least five years. The authority must evaluate businesses using factors such as market opportunity, financial stability, management experience, business plan, competitive assets, projected economic benefits, and projected social benefits. Investments must be made with a co-investor selected through a competitive process, and the authority’s share may not exceed one-third of the combined investment.
SB119 also imposes contractual protections and repayment rules. If a portfolio business fails to meet its obligations, it must either reimburse the authority’s cost basis or show that it delivered economic benefits exceeding that amount. The bill requires an acquiring entity to assume the contract in a majority sale, gives the authority first claim in bankruptcy or liquidation, and allows stock to be accepted in lieu of cash in certain circumstances with approval from the state investment council. It further adds reporting requirements, including quarterly investment reports to the board and annual reporting to the governor and legislature.
The bill appropriates $25 million from the general fund to the bioscience development fund for fiscal year 2026 and later years, with unspent balances not reverting to the general fund. It also makes the fund’s money available for the new investment program and keeps the existing nonreversion structure. In addition, the bill creates ethics-related employment restrictions for entities that receive authority support, barring certain hiring relationships with board members and authority employees, and makes knowing and willful violations a fourth-degree felony.
The available voting history suggests the bill had majority support in the Senate, passing final passage 26-15. No committee transcript is available, so the record does not show detailed debate, but the structure of the bill suggests support from economic development advocates and likely concern from members wary of state equity investing, the size of the appropriation, the felony penalty, and the risk of public funds being placed in private companies.
SB119 would materially expand the Bioscience Development Act by authorizing the bioscience authority to make equity-style investments in bioscience businesses and by establishing eligibility, oversight, reporting, reimbursement, and conflict-of-interest rules for those investments. It would also appropriate $25 million from the general fund to the bioscience development fund and make those funds available for investment beginning in fiscal year 2026. The bill affects the Bioscience Development Act, the state treasury’s bioscience development fund, and related oversight by the authority, the secretary of economic development, the state investment council, and law enforcement officials for enforcement of the new felony provision.
The bill appears to have generally favorable support among a majority of senators, as reflected in its 26-15 final passage vote. The overall policy direction is pro-economic-development and pro-bioscience-industry, with an emphasis on attracting or retaining high-wage bioscience jobs in New Mexico. At the same time, the vote margin indicates meaningful opposition or concern, likely centered on the use of public money for private investments, the adequacy of safeguards, and the bill’s enforcement provisions.
Likely points of contention include whether the state should directly invest in private bioscience companies at all, whether the $25 million appropriation is an appropriate use of general fund dollars, and whether the bill’s safeguards are sufficient to protect taxpayers. The requirement that recipient businesses maintain five in-state employees at an average salary of $60,000, the one-third co-investment cap, and the reimbursement/first-claim provisions are designed to reduce risk, but critics may still question the state’s exposure if investments underperform. The new felony penalty for prohibited hiring relationships may also be controversial as a strong enforcement mechanism for an ethics-related restriction.